Antibody-Drug Conjugates for Ovarian Cancer — An Interview with Dr Kathleen N Moore (Companion Faculty Lecture)

Research To Practice | Oncology Videos · Feb 9, 2026 · 36m

Featuring a slide presentation and related discussion from Dr Kathleen N Moore, including the following topics:

Overview of developments and opportunities with antibody-drug conjugates (ADCs) in ovarian cancer(0:00)

Targeting folate receptor alpha with mirvetuximab soravtansine (3:59)

Targeting TROP2 with ADCs (9:12)

Targeting folate receptor alpha with ADCs (14:17)

Targeting cadherin-6 with ADCs (17:27)

Targeting HER2 with ADCs (26:12)

Potential of ADCs in the treatment of platinum-sensitive ovarian cancer (28:38)

CME information and select publications